Aura Biosciences, Inc. (AURA) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Aura Biosciences reported revenue of $0. Net income was -$106.2M, or -$1.76 per diluted share. Operating activities generated -$84.7M of cash, leaving -$85.1M of free cash flow. At fiscal year end, Aura Biosciences held $169.4M in total assets against $32.5M in total liabilities, including $59.5M of cash and equivalents.
Open the full interactive Aura Biosciences financials → Quarterly statements, key ratios, valuation history and price charts.
Aura Biosciences Key Stats
| Share Price | $6.27 |
|---|---|
| Market Cap | $594.8M |
| 52-Week Range | $4.97 – $8.90 |
| Shares Outstanding | 94.9 million (basic, 2026 Q2) |
Aura Biosciences Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$35.2M | -$60.3M | -$85.0M | -$96.1M | -$112.8M |
| Pre-Tax Income | -$35.3M | -$58.8M | -$76.3M | -$86.8M | -$106.1M |
| Income Tax | $0 | $0 | $137,000 | $112,000 | $108,000 |
| Net Income | -$35.3M | -$58.8M | -$76.4M | -$86.9M | -$106.2M |
| Diluted EPS | -$8.95 | -$1.96 | -$1.93 | -$1.75 | -$1.76 |
Aura Biosciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$26.1M | -$25.6M | -$33.7M | -$45.6M |
| Diluted EPS | -$0.40 | -$0.42 | -$0.50 | -$0.48 |
Aura Biosciences Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $149.1M | $121.6M | $41.1M | $31.7M | $59.5M |
| Current Assets | $153.7M | $196.7M | $231.8M | $160.6M | $149.7M |
| Total Assets | $160.0M | $223.9M | $255.1M | $182.5M | $169.4M |
| Current Liabilities | $7.3M | $10.5M | $12.4M | $14.9M | $18.4M |
| Total Liabilities | $7.7M | $28.4M | $29.2M | $30.5M | $32.5M |
| Shareholders' Equity | $152.3M | $195.6M | $225.8M | $152.0M | $136.9M |
Aura Biosciences Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$32.4M | -$54.6M | -$63.8M | -$79.8M | -$84.7M |
| Cash From Investing | -$2.1M | -$67.9M | -$114.0M | $68.8M | $35.6M |
| Cash From Financing | $166.3M | $95.6M | $97.3M | $1.6M | $77.2M |
| Free Cash Flow | -$34.5M | -$55.7M | -$64.6M | -$81.1M | -$85.1M |
Figures from Aura Biosciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Aura Biosciences financials page for every line item.
Aura Biosciences Company Profile
| Ticker | AURA |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Boston, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company, emerging growth company |
| SEC CIK | 0001501796 |
Frequently Asked Questions
What was Aura Biosciences' revenue in fiscal 2025?
Aura Biosciences (AURA) reported revenue of $0 for fiscal 2025.
What is Aura Biosciences' annual revenue history?
Aura Biosciences' annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Aura Biosciences' net income in fiscal 2025?
Aura Biosciences reported net income of -$106.2M for fiscal 2025.
What was Aura Biosciences' earnings per share (EPS) in fiscal 2025?
Aura Biosciences' diluted EPS was -$1.76 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Aura Biosciences generate in fiscal 2025?
Aura Biosciences generated -$85.1M of free cash flow in fiscal 2025.
What was Aura Biosciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), Aura Biosciences reported revenue of $0.
How many shares of Aura Biosciences are outstanding?
Aura Biosciences reported a weighted average of 94.9 million basic shares outstanding in 2026 Q2.
What is Aura Biosciences' market cap?
Based on its latest closing price, Aura Biosciences (AURA) has a market capitalization of about $594.8M.
When does Aura Biosciences' fiscal year end?
Aura Biosciences' fiscal year end, as registered with the SEC, is December 31.
Where is Aura Biosciences headquartered?
Aura Biosciences lists its business address in Boston, Massachusetts in its SEC filings.
Aura Biosciences Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →